??????????????????? ??????

??????+??????????. 10mm. 6010mm². 0~ 5.0MPa. ?. ???????? ... ??????????????????????????????? ???? ...







??? ????? - <?????????? >
|??. ?????. ??. ???????????. ????????????. ????????????. ?????????? ???????????. ?????? ...
?????????????????????????? ???? ...
???????DC12V???????. DRUM PUMP (AIR OPERATED). ??? ... SP-TD?????????. ????????????. ?1,100?1,400mm ...
? ? ? ?
????????????????????????????????. ????? ... ??????. ??????. Ti?SUS?PVC?PTFE?FKM?PVDF?PP????.
PG-300 | HORIBA
??????????????????? ????????????????????????? ????????????????????
???????????
?????????????????????????????????????????. ?????? ?????????????????????????????? ...
UTM3400 ???? ????? - ULVAC SHOWCASE
???????????????????????????? ??????. IZS31 Series. ?????? ??????. IZN10 Series.
??????????
????????????????????????????????. ??????????????????????????????????? CP-DFP-J. ??????.
Thalidomide: An Overview and the Species-Specific Teratogenicity
Conclusion: Outside clinical trials, vtD remains a superior induction regimen compared with TD in transplant-eligible, newly diagnosed patients ...
16-Thalidomide and dexamethasone oral SUPERSEDED | eviQ
They showed that single-agent thalidomide can induce a partial response in approximately 30% of patients with refractory myeloma. The combination of thalido-.
Thalidomide for Treating Metastatic Hepatocellular Carcinoma
Furthermore, the TD regimen was administered to eight patients with primary refractory myeloma who were eligible for high-dose therapy with autologous stem cell.
The Thalidomide Story
Thalidomide (TD) was first developed as a safe sedative hypnotic in 1958 and was prescribed for pregnant women to prevent morning sickness.
Immunomodulatory agents: Thalidomide - Knowledge Hub
Résumé. Le thalidomide, molécule tératogène retirée du marché en 1961, quatre ans après sa commercialisation est à l'origine de malformations graves ayant ...